Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark.
Pharm Res. 2013 Dec;30(12):3101-13. doi: 10.1007/s11095-013-1145-x. Epub 2013 Aug 15.
To investigate the effect of increasing the loading level of the poorly soluble drug cinnarizine in a self-nanoemulsifying drug delivery system (SNEDDS) both in vitro and in vivo.
A fixed dose of cinnarizine was administered orally to dogs in solution in different amounts of SNEDDS vehicle. Furthermore, the SNEDDSs were characterised using the dynamic in vitro lipolysis model.
Statistical differences in bioavailability were not obtained between the different amounts of SNEDDS vehicle, in spite of differences in the tendency of cinnarizine to precipitate during in vitro lipolysis of the treatments. Use of the SNEDDS concept decreased the variation in cinnarizine exposure observed between dogs as compared to administering cinnarizine in an aqueous suspension.
Optimization of SNEDDSs towards keeping the drug compound in solution upon in vitro lipolysis of the SNEDDSs may not be as important as previously suggested.
考察在自微乳药物传递系统(SNEDDS)中增加难溶性药物桂利嗪的载药量的体外和体内效果。
以不同剂量的 SNEDDS 载体给狗口服给予固定剂量的桂利嗪溶液。此外,使用动态体外脂肪酶模型对 SNEDDS 进行了表征。
尽管在处理物的体外脂肪酶分解过程中桂利嗪沉淀的趋势不同,但不同剂量的 SNEDDS 载体之间的生物利用度没有统计学差异。与将桂利嗪制成水溶液给予相比,使用 SNEDDS 概念降低了狗之间观察到的桂利嗪暴露的变异性。
优化 SNEDDS 以保持药物化合物在 SNEDDS 的体外脂肪酶分解时处于溶液状态,可能不如先前建议的那么重要。